Literature DB >> 15063480

Pharmacological profile of progestins.

Regine Sitruk-Ware1.   

Abstract

The synthetic progestins used so far for contraception and menopausal hormone therapy are derived either from testosterone (19-nortestosterone derivatives) or from progesterone (17-OH progesterone derivatives and 19-norprogesterone derivatives). Among the 19-nortestosterone derivatives, the estrane group include norethisterone (NET) and its metabolites, and the gonane group include levonorgestrel (LNG) and its derivatives. The later, including desogestrel (DSG) and its derivative etonogestrel, gestodene (GES) and norgestimate (norelgestromin), have been referred to as third-generation progestins. Several new progestins have been synthesized in the last decade and may be considered as a fourth-generation of progestins. Dienogest is referred to as a hybrid progestin being derived from the estrane group with a 17alpha-cyanomethyl group, and drospirenone derives from spirolactone. These two progestins have no androgenic effect but a partial antiandrogenic effect. The later exerts anti-mineralocorticoid effects. This property leads to a decreased salt and water retention and a lowering in blood pressure in users of pills containing this progestin. The 19-norprogesterone derivatives appear more specifically progestational and do not possess any androgenic, estrogenic or glucocorticoid activity. They are referred to as "pure" progestational molecules as they bind almost exclusively to the progesterone receptor (PR) and do not interfere with the other steroid receptor. This category includes, trimegestone, nomegestrol acetate and Nestorone is not active orally but proved to be a potent anti-ovulatory agent when given in implants, vaginal rings or percutaneous gel. Non-androgenic progestins would appear neutral on metabolic factors and on the vessels and would have the advantage of avoiding acnea. Progestins with antiandrogenic properties may also be used for the treatment of women with preexisting androgen related conditions. The progestins available for therapy exhibit profound differences according to their structure or metabolites and it is inappropriate to consider the various effects of the old and new molecules as class-effects.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15063480     DOI: 10.1016/j.maturitas.2004.01.001

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  42 in total

Review 1.  Comprehensive review of cardiovascular toxicity of drugs and related agents.

Authors:  Přemysl Mladěnka; Lenka Applová; Jiří Patočka; Vera Marisa Costa; Fernando Remiao; Jana Pourová; Aleš Mladěnka; Jana Karlíčková; Luděk Jahodář; Marie Vopršalová; Kurt J Varner; Martin Štěrba
Journal:  Med Res Rev       Date:  2018-01-05       Impact factor: 12.944

2.  Cutaneous postural vasoconstriction is modified by exogenous but not endogenous female hormones in young women.

Authors:  Gemma D Bishop; Margaret D Brown
Journal:  Clin Auton Res       Date:  2007-01-30       Impact factor: 4.435

3.  Comparing the androgenic and estrogenic properties of progestins used in contraception and hormone therapy.

Authors:  Renate Louw-du Toit; Meghan S Perkins; Janet P Hapgood; Donita Africander
Journal:  Biochem Biophys Res Commun       Date:  2017-07-12       Impact factor: 3.575

4.  Effects of long-term treatment with estrogen and medroxyprogesterone acetate on synapse number in the medial prefrontal cortex of aged female rats.

Authors:  Nioka C Chisholm; Janice M Juraska
Journal:  Menopause       Date:  2012-07       Impact factor: 2.953

5.  Continuous dosing of a novel contraceptive vaginal ring releasing Nestorone® and estradiol: pharmacokinetics from a dose-finding study.

Authors:  J T Jensen; A B Edelman; B A Chen; D F Archer; K T Barnhart; M A Thomas; A E Burke; C L Westhoff; L S Wan; R Sitruk-Ware; N Kumar; B Variano; D L Blithe
Journal:  Contraception       Date:  2018-02-02       Impact factor: 3.375

6.  Dienogest, a selective progestin, reduces plasma estradiol level through induction of apoptosis of granulosa cells in the ovarian dominant follicle without follicle-stimulating hormone suppression in monkeys.

Authors:  S Sasagawa; Y Shimizu; T Nagaoka; H Tokado; K Imada; K Mizuguchi
Journal:  J Endocrinol Invest       Date:  2008-07       Impact factor: 4.256

Review 7.  Progesterone receptor signaling in the initiation of pregnancy and preservation of a healthy uterus.

Authors:  Margeaux Wetendorf; Francesco J DeMayo
Journal:  Int J Dev Biol       Date:  2014       Impact factor: 2.203

Review 8.  Contraceptive hormone use and cardiovascular disease.

Authors:  Chrisandra L Shufelt; C Noel Bairey Merz
Journal:  J Am Coll Cardiol       Date:  2009-01-20       Impact factor: 24.094

Review 9.  Progesterone signalling in breast cancer: a neglected hormone coming into the limelight.

Authors:  Cathrin Brisken
Journal:  Nat Rev Cancer       Date:  2013-06       Impact factor: 60.716

Review 10.  Safety, efficacy and patient acceptability of drospirenone and estradiol in the treatment of menopausal vasomotor symptoms: a review.

Authors:  Sebastián Carranza-Lira
Journal:  Clin Interv Aging       Date:  2009-05-14       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.